

# CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023

<https://marketpublishers.com/r/C9DB6FF3A76EN.html>

Date: October 2017

Pages: 500

Price: US\$ 3,300.00 (Single User License)

ID: C9DB6FF3A76EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered. Although the potential of antibodies was well understood but it required a series of discoveries to find out that specific antibodies are capable of targeting one unique molecular site of the cancer cells.

“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights:

Market Opportunity Assessment: More than US\$ 60 Billion by 2023

Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs

Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline

Dosage & Price Analysis on Key Drugs

Mechanism of CD Antigen Cancer Therapeutics

## Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs

### Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase

CD antigens have been used as targets in a wide variety of cancer therapeutics including monoclonal antibodies, antibody-drug-conjugates, tri-functional and bi-specific T-cell engager antibodies, radio immunoconjugates and CAR T-cell therapies. The current scenario clearly indicates that CD Antigens have acquired a major share in the modern cancer therapy market. Approval and commercialization of such a wide variety of cancer therapeutics have shown that continuous efforts have been made to produce unique and improved anti-cancer products.

Global CD antigen based cancer therapy market has evolved since the approval of first CD antigen targeting monoclonal antibody. Current market is fledged with a variety of CD antigen targeting cancer therapies. The market has successfully produced unique CD antigen based cancer therapies. Clinical trials of these therapies have provided evidences that they are better than the existing conventional cancer therapies and provide better quality adjusted life years and prolonged survival to cancer patients.

Although current global CD antigen based cancer therapeutic market is dominated for treating hematological malignancies but strong clinical pipeline having over 100 CD antigen directing cancer drugs consists of various drugs which will be used for treating solid tumors like breast cancer, lung cancer, colorectal cancer, prostate cancer etc. As the number of patients suffering from solid tumors is much higher than the patients suffering from hematological malignancies; an exponential growth can be experienced by Global CD Antigen Cancer Therapy Market after the approval of anti-CD antigenic cancer drugs for treating solid tumors.

The future CD antigen based cancer therapy market is going to be highly competitive as the pharmaceutical companies have to ensure that they are producing unique and more advanced products. Furthermore, CD antigens based cancer therapies has the potential to become popular amongst the patients and physicians as they provide better survival and have justified their high prices in case of some therapies by providing better clinical results than other conventional cancer therapies.

## Contents

### **1. INTRODUCTION TO CD ANTIGEN BASED CANCER THERAPEUTICS**

- 1.1 Prologue to CD Antigens
- 1.2 Background: Discovering CD Antigens in Cancer Therapy
- 1.3 Historical Aspects of CD Antigen Based Cancer Therapeutics

### **2. SIGNIFICANCE OF CD ANTIGENS: NORMAL CELLS VERSUS CANCER CELLS**

- 2.1 CD Antigens in Normal Cells
- 2.2 CD Antigens in Cancer

### **3. WORKING MECHANISM OF CD ANTIGEN BASED CANCER THERAPEUTICS**

### **4. COMMERCIAL CANCER THERAPEUTICS BASED ON CD ANTIGENS**

- 4.1 Monoclonal Antibodies
- 4.2 Antibody Drug Conjugates
- 4.3 Bispecific Antibodies

### **5. RECENT COMMERCIAL TRENDS IN CD ANTIGEN BASED CANCER THERAPEUTICS**

- 5.1 CAR-T Cell Therapy
- 5.2 Aptamers
- 5.3 Immunoconjugates
  - 5.3.1 Radio Immunoconjugate
  - 5.3.2 Toxin Immunoconjugate
- 5.4 Novel CD Antigen Based Antibodies
  - 5.4.1 Bispecific T-Cell Engager Antibody (BiTEs)
  - 5.4.2 DART and TandAb

### **6. MAJOR CD ANTIGENS AS TARGETS FOR CANCER THERAPY**

- 6.1 CD20
- 6.2 CD19
- 6.3 CD137
- 6.4 CD38

6.5 CD70

6.6 CD22

6.7 CD30

6.8 CD33

6.9 CD37

## **7. MAJOR CD ANTIGENS AS CANCER DIAGNOSTIC AGENTS**

7.1 CD20

7.2 CD5

7.3 CD56

7.4 CD66e

7.5 CD15

7.6 CD30

7.7 CD3

## **8. MAJOR CD ANTIGENS IN CANCER RESEARCH**

8.1 CD34

8.2 CD10

8.3 CD26

8.4 CD117

8.5 CD44

8.6 CD57

## **9. GLOBAL CD ANTIGEN BASED THERAPEUTICS MARKET OVERVIEW**

9.1 Market Progression

9.2 Current Market Scenario

9.3 Global CD Antigen Based Cancer Therapeutics Market Trends

9.4 Global Cancer CD Antigen Inhibitors Pipeline Overview

## **10. PRICE & DOSAGE ANALYSIS OF MAJOR CD ANTIGEN BASED CANCER THERAPIES**

10.1 Rituximab (CD20)

10.2 Ofatumumab (CD20)

10.3 Obinutuzumab (CD20)

10.4 Daratumumab (CD38)

- 10.5 Brentuximab Vedotin (CD30)
- 10.6 Gemtuzumab Ozogamicin (CD33)
- 10.7 Inotuzumab Ozogamicin (CD22)
- 10.8 Ibritumomab Tiuxetan (CD20)
- 10.9 Blinatumomab (CD19, CD3)
- 10.10 Tisagenlecleucel (CD19)

## **11. MARKETING CANCER CD ANTIGEN INHIBITORS CLINICAL & PATENT INSIGHT**

- 11.1 Rituximab (MabThera & Rituxan)
- 11.2 Obinutuzumab (Gazyva & Gazyvaro)
- 11.3 Ibritumomab Tiuxetan (Zevalin & Zevamab)
- 11.4 Rituximab Biosimilar (AcellBia & USMAL)
- 11.5 Rituximab Biosimilar (Reditux & Tidecron)
- 11.6 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
- 11.7 Rituximab Biosimilar (Novex)
- 11.8 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
- 11.9 Rituximab Biosimilar (Maball)
- 11.10 Rituximab Biosimilar (Kikuzubam)
- 11.11 Rituximab Biosimilar (Mabtas)
- 11.12 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
- 11.13 Avelumab (BAVENCIO)
- 11.14 Pembrolizumab (Keytruda)
- 11.15 Atezolizumab (TECENTRIQ)
- 11.16 Durvalumab (Imfinzi)
- 11.17 Rituximab Biosimilar (Zytux)

## **12. GLOBAL CD ANTIGEN CANCER THERAPY MARKET DYNAMICS**

- 12.1 Market Growth Drivers
  - 12.1.1 Large Patient Base
  - 12.1.2 Unmet Medical Need
  - 12.1.3 Better Safety Profile
  - 12.1.4 Accelerated Research & Development: Newly Identified CD Antigens in Cancer
  - 12.1.5 Acquiring Major Share of the Modern Cancer Therapy Market
  - 12.1.6 Strong Clinical Pipeline
- 12.2 CD Antigen Market Challenges
  - 12.2.1 High Prices of CD Antigen Based Cancer Therapeutics

12.2.2 Difficulties in Differentiating CD Target on Cancer Cells

12.2.3 High Production Cost Due to Complex Structure

### **13. GLOBAL CD ANTIGENS CANCER THERAPY MARKET FUTURE FORECAST**

### **14. CANCER CD ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

14.1 Research

14.2 Preclinical

14.3 Phase-I

### **15. CANCER CD3 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

15.1 Preclinical

15.2 Phase-I

15.3 Phase-II

### **16. CANCER CD4 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

16.1 Phase-I

### **17. CANCER CD7 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

17.1 Preclinical

### **18. CANCER CD19 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

18.1 Phase-I

18.2 Phase-I/II

18.3 Phase-II

18.4 Phase-III

### **19. CANCER CD20 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 19.1 Unknown
- 19.2 Research
- 19.3 Preclinical
- 19.4 Clinical
- 19.5 Phase-I
- 19.6 Phase-I/II
- 19.7 Phase-II
- 19.8 Phase-III
- 19.9 Registered

## **20. CANCER CD22 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 20.1 Preclinical
- 20.2 Phase-III
- 20.3 Registered

## **21. CANCER CD 26 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 21.1 Preclinical
- 21.2 Phase-I/II

## **22. CANCER CD27 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 22.1 Research
- 22.2 Preclinical
- 22.3 Phase-II

## **23. CANCER CD30 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 23.1 Phase-I

## **24. CANCER CD33 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

24.1 Phase-I

24.2 Phase-I/II

## **25. CANCER CD38 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

25.1 Research

25.2 Preclinical

25.3 Phase-I/II

25.4 Phase-III

## **26. CANCER CD44 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

26.1 Preclinical

26.2 Phase-I

## **27. CANCER CD45 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

27.1 Phase-III

## **28. CANCER CD46 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

28.1 Research

## **29. CANCER CD 47 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

29.1 Research

29.2 Preclinical

29.3 Phase-I

29.4 Phase-I/II

## **30. CANCER CD52 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

30.1 Research



## 30.2 Preclinical

### **31. CANCER CD55 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 31.1 Preclinical

#### 31.2 Phase-II

### **32. CANCER CD56 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 32.1 Phase-II

### **33. CANCER CD66 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 33.1 Phase-I

### **34. CANCER CD70 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 34.1 Phase-II

### **35. CANCER CD71 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 35.1 Preclinical

### **36. CANCER CD98 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 36.1 Phase-I

### **37. CANCER CD200 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

#### 37.1 Preclinical

#### 37.2 Clinical

#### 37.3 Phase-II

### **38. CANCER CD223 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 38.1 Preclinical
- 38.2 Phase-I
- 38.3 Phase-I/II
- 38.4 Phase-II

### **39. CANCER CD248 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 39.1 Preclinical
- 39.2 Phase-II

### **40. CANCER CD274 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 40.1 Research
- 40.2 Preclinical
- 40.3 Clinical
- 40.4 Phase-I
- 40.5 Phase-I/II

### **41. CANCER CD319 ANTIGEN INHIBITOR CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 41.1 Phase-I

### **42. CANCER MULTIPLE ANTIGEN INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 42.1 Preclinical
- 42.2 Phase-I
- 42.3 Phase-I/II

### **43. COMPETITIVE LANDSCAPE**

- 43.1 AryoGen Biopharma

- 43.2 Biocad
- 43.3 Biogen Idec
- 43.4 Celltrion
- 43.5 Genentech
- 43.6 Genmab
- 43.7 GLYCART Biotechnology
- 43.8 Hetero Drugs
- 43.9 mAbxience
- 43.10 MedImmune
- 43.11 Merck
- 43.12 Sandoz
- 43.13 UCB

## List Of Figures

### LIST OF FIGURES

Figure 1-1: Evolution of CD Antigen Based Therapeutic Antibodies in Cancer Therapy

Figure 2-1: CD Antigens as Markers on Normal Leukocytes

Figure 2-2: Significance of CD Antigen in Cancer Cell & its Inhibition by Therapeutic Antibody

Figure 4-1: Types of CD Antigen Based Cancer Therapeutics

Figure 4-2: Structure of Monoclonal Antibody

Figure 4-3: Types of Therapeutic Monoclonal Antibodies

Figure 4-4: Architecture of Antibody Drug Conjugates

Figure 4-5: Bispecific Antibody Structure

Figure 5-1: Advanced CD Antigen Targeting Cancer Therapies

Figure 5-2: Structure of Radio Immunoconjugate

Figure 5-3: Structure of Bispecific T-Cell Engager Antibody

Figure 5-4: Structure of Dual Affinity Re-Targeting Antibody

Figure 6-1: Mechanism of Action of Anti-CD20 Monoclonal Antibody Rituximab

Figure 6-2: Mechanism of Action of Anti-CD30 Antibody Drug Conjugate Brentuximab Vedotin

Figure 9-1: Global - Cancer Therapeutic Monoclonal Antibody Market Share (%), 2017

Figure 9-2: Global - CD20 Cancer Therapeutic Segmentation by Region (%), 2017

Figure 9-3: Global - Rituximab Sales (US\$ Billion), 2013-2016

Figure 9-4: Global - Ofatumumab Sales (US\$ Million), 2013-2016

Figure 9-5: Global - Obinutuzumab Sales (US\$ Million), 2015 & 2016

Figure 9-6: Global - Ibritumomab Tiuxetan Sales (US\$ Million), 2013-2016

Figure 9-7: Global - Daratumumab Sales (US\$ Million), 2015-2017\*

Figure 9-8: Global - Daratumumab Half Yearly Sales (US\$ Million), 2016 & 2017

Figure 9-9: Global - Brentuximab Vedotin Sales (US\$ Million), 2014-2017

Figure 9-10: Global - Blinatumomab Sales (US\$ Million), 2015-2017\*

Figure 9-11: Global - Blinatumomab Sales (US\$ Million), 2015-2017

Figure 9-12: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-13: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 9-14: Global - Cancer CD3 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-15: Global - Cancer CD3 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-16: Global - Cancer CD19 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-17: Global - Cancer CD19 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-18: Global - Cancer CD20 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-19: Global - Cancer CD20 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-20: Global - Cancer CD22 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-21: Global - Cancer CD22 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-22: Global - Cancer CD26 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-23: Global - Cancer CD26 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-24: Global - Cancer CD27 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-25: Global - Cancer CD27 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-26: Global - Cancer CD33 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-27: Global - Cancer CD33 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-28: Global - Cancer CD38 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-29: Global - Cancer CD38 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-30: Global - Cancer CD44 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-31: Global - Cancer CD44 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-32: Global - Cancer CD47 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-33: Global - Cancer CD47 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-34: Global - Cancer CD52 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-35: Global - Cancer CD52 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

till 2023

Figure 9-36: Global - Cancer CD55 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-37: Global - Cancer CD55 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-38: Global - Cancer CD200 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-39: Global - Cancer CD200 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-40: Global - Cancer CD223 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-41: Global - Cancer CD223 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-42: Global - Cancer CD248 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-43: Global - Cancer CD248 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-44: Global - Cancer CD274 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023

Figure 9-45: Global - Cancer CD274 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023

Figure 9-46: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-47: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (Number), 2017

Figure 9-48: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023

Figure 9-49: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023

Figure 10-1: US - Rituximab Intravenous Solution Price by Concentration (10mg/mL) (US\$/Unit), 2017

Figure 10-2: US - Rituximab Vial Price by Quantity (US\$), 2017

Figure 10-3: Rituximab Treatment Cost Analysis by Route of Administration (US\$), 2017

Figure 10-4: US - Ofatumumab Intravenous Solution Price by Concentration (20mg/mL) (US\$/Unit), 2017

Figure 10-5: US - Ofatumumab Vial Price by Quantity (US\$), 2017

Figure 10-6: Ofatumumab - Treatment Dosage Analysis (mg)

Figure 10-7: Ofatumumab - Price Analysis by Dosage (US\$)

Figure 10-8: Obinutuzumab First Cycle Dosage Analysis (mg)

Figure 10-9: Obinutuzumab Treatment Dosage Analysis (mg)

Figure 10-10: US - Obinituzumab Solution Price (US\$), 2017

Figure 10-11: Obinutuzumab - Therapy First Cycle Average Cost (US\$), 2017

Figure 10-12: Obinutuzumab Average Treatment Cost (US\$), 2017

Figure 10-13: Daratumumab Monotherapy Dosage Analysis (mg)

Figure 10-14: Daratumumab Combination Therapy Dosage Analysis (mg)

Figure 10-15: US - Daratumumab Intravenous Solution Cost by Concentration (20mg/mL) (US\$/Unit), 2017

Figure 10-16: Daratumumab Vial Price Analysis by Quantity (US\$), 2017

Figure 10-17: Daratumumab Monotherapy Average Cost Analysis (US\$), 2017

Figure 10-18: Daratumumab Combination Therapy Average Cost Analysis (US\$), 2017

Figure 10-19: US - Brentuximab Vedotin Price Analysis, (US\$), 2017

Figure 10-20: US - Brentuximab Vedotin Treatment Expenditure (US\$), 2014

Figure 10-21: US - Brentuximab Vedotin Treatment Cost (US\$), 2017

Figure 10-22: Global - Gemtuzumab Ozogamicin Treatment Cycle Price Analysis (US\$), 2010 & 2017

Figure 10-23: US - Ibritumomab Tiuxetan Product & Dose Price Analysis (US\$), 2017

Figure 10-24: US - Blinatumomab Dosage Average Price Analysis (US\$), 2017

Figure 10-25: US - Blinatumomab Treatment First Cycle Average Cost (US\$), 2017

Figure 10-26: US - Blinatumomab Treatment Subsequent Cycle Average Cost (US\$), 2017

Figure 12-1: Global CD Antigen Based Cancer Therapy Market Driving Factors

Figure 12-2: Gemtuzumab vs Best Available Therapy Survival Rate

Figure 12-3: Global CD Antigen Based Cancer Therapeutic Market Challenges

## List Of Tables

### LIST OF TABLES

Table 10-1: Rituximab Dosage Indications for Treatment of Different Cancer Conditions



## I would like to order

Product name: CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023

Product link: <https://marketpublishers.com/r/C9DB6FF3A76EN.html>

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9DB6FF3A76EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970